The Phase 2a trial of bexotegrast demonstrated a reduction in total lung collagen levels as measured by PET imaging. Can you explain the significance of this finding for IPF patients, and how it suggests a potential reversal of fibrosis?

Bexotegrast-treated patients showed improvements in FVC across all timepoints. How do these improvements translate into clinical benefits for IPF patients, and what does it mean for the progression of the disease?

Chronic cough is a debilitating symptom for many IPF patients. The trial reported a reduction in cough severity for those treated with bexotegrast. How important is this outcome for patient quality of life and overall disease management?

The trial assessed several exploratory efficacy endpoints, including changes in fibrosis biomarkers. Can you discuss the relevance of these biomarkers in IPF treatment and how bexotegrast’s impact on these markers supports its therapeutic potential?

Bexotegrast was well tolerated with no serious adverse events reported over the 12-week treatment period. How do these safety results compare with other IPF treatments, and what implications do they have for long-term use of bexotegrast?

This study utilized PET imaging with a collagen-binding radiotracer to measure treatment effects. Can you elaborate on the advantages of using this novel imaging technique in clinical trials for IPF, and how it may impact future research and treatment approaches?

Most patients in the trial were on standard IPF therapy, primarily nintedanib. How does the addition of bexotegrast to existing treatments potentially enhance patient outcomes, and what are the benefits of this combination therapy?

Considering the results from this Phase 2a trial, what are the next steps in the development of bexotegrast for IPF? Are there plans to explore its efficacy in other fibrotic diseases or conditions beyond IPF?